BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First published online January 5, 2009
British Journal of Radiology (2009) 82, 468-484
© 2009 British Institute of Radiology
doi: 10.1259/bjr/76535286
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by KIM, Y K
Right arrow Articles by HAN, Y M
PubMed
Right arrow PubMed Citation
Right arrow Articles by KIM, Y K
Right arrow Articles by HAN, Y M
British Journal of Radiology 82 (2009),468-484 ©2009 The British Institute of Radiology

Detection of small hepatocellular carcinoma: comparison of conventional gadolinium-enhanced MRI with gadolinium-enhanced MRI after the administration of ferucarbotran

Y K KIM, MD C S KIM, MD and Y M HAN, MD

Department of Diagnostic Radiology, Chonbuk National University Hospital and Medical School, Keum Am Dong, JeonJu, South Korea

Correspondence: Young Kon Kim, Department of Diagnostic Radiology, Chonbuk National University Hospital and Medical School, Keum Am Dong, JeonJu, South Korea. E-mail: jmyr{at}dreamwiz.com

We compared the diagnostic efficacy of gadolinium (Gd)-enhanced MRI with that of Gd-enhanced MRI after administration of ferucarbotran for revealing small hypervascular hepatocellular carcinomas (HCCs). 24 patients with 34 HCCs (ranging in size from 0.6–2.0 cm) underwent Gd-enhanced three-dimensional dynamic MRI followed, after an interval of 5–11 days (mean, 7 days), by Gd-enhanced three-dimensional dynamic MRI after administration of ferucarbotran. The two Gd-enhanced arterial-phase MRI scans were compared quantitatively by measuring the tumour–liver contrast-to-noise ratio (CNR) and qualitatively by evaluating the tumour–liver contrast using matched-pairs analysis. The tumour–liver CNR with Gd-enhanced arterial-phase imaging after ferucarbotran (250.3 ± 103.7) was higher than that with Gd-enhanced arterial-phase imaging (221.1 ± 96.1) (p < 0.001). Matched-pairs analysis indicated that, for three lesions, the relative tumour–liver contrast was slightly better with Gd-enhanced arterial-phase imaging after ferucarbotran than with conventional Gd-enhanced arterial-phase imaging; however, in the case of the remaining 31 lesions, the two images were equivalent. We concluded that, although Gd-enhanced arterial-phase imaging after ferucarbotran results in better tumour–liver CNR than Gd-enhanced arterial-phase imaging, the ability of the two techniques to reveal small hypervascular HCCs is the same.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2009 by the British Institute of Radiology.